William H. Frey II, PhD, CEO of IntrepiCyte LLC, has served many years as senior research director in the Center for Memory and Aging at the HealthPartners Neuroscience Center as well as professor in the graduate program in neuroscience at the University of Minnesota. Dr. Frey’s noninvasive intranasal method for bypassing the blood-brain barrier to target therapeutic agents directly to the brain in order to treat neurologic, psychiatric, and behavioral disorders while reducing unwanted side effects has captured the interest of both pharmaceutical companies and neuroscientists. The intranasal insulin treatment, invented by Frey, has been shown in multiple clinical trials to safely improve memory and also increase brain cell energy. The noninvasive intranasal method of bypassing the blood-brain barrier to deliver and target therapeutic cells to the central nervous system, invented with Lusine Danielyan, MD, has been shown to be effective in multiple animal studies in labs around the world and, more recently, has been tested in clinical trials. With numerous publications in scientific and medical journals, Frey has been interviewed by media outlets around the world. Dr. Frey earned his BA in chemistry at Washington University and his PhD in biochemistry at Case Western Reserve University.